Dermisonics

Dermisonics produces ultrasound transdermal drug delivery technology and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch (called U-Strip), which is designed to facilitate needle-free delivery of drugs with large molecular structures, such as insulin, into the bloodstream. The company, formerly known as Second Stage Ventures, was renamed Dermisonics in October 2004.